CNS Pharmaceuticals, Inc. (CNSP) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	10-K
Revenues	15.4	0.0	0.0	0.0	0.0
Revenue growth				-100.0%
Cost of goods sold	0.1	0.0	0.0	0.0	-1.8
Gross profit	15.4	0.0	0.0	0.0	1.7
Gross margin	99.5%				-6063.1%
Selling, general and administrative [+]	6.0	4.7	4.4	2.0	0.9
General and administrative	6.0	4.7	4.4	2.0	0.9
Research and development	9.3	9.8	5.1	1.9	0.0
Other operating expenses	15.3				1.7
EBITDA [+]	-15.2	-14.5	-9.4	-3.8
EBITDA growth	4.7%	53.3%	146.5%	334.5%
EBITDA margin	-98.1%				3081.6%
Depreciation and amortization	0.0	0.0	0.0	0.0
EBIT [+]	-15.2	-14.5	-9.5	-3.8	-0.9
EBIT growth	4.7%	53.2%	146.7%	334.7%
EBIT margin	-98.2%				3081.6%
Non-recurring items	0.1
Interest expense	0.0	0.0	0.0	0.0
Interest expense	0.0	0.0	0.0	0.0
Other income (expense), net [+]				0.0	-6.5
Amortization of debt discount premium				0.0	0.0
Pre-tax income	-15.3	-14.5	-9.5	-3.9	-7.4
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-15.3	-14.5	-9.5	-3.9	-7.4
Net margin	-98.9%				25832.3%

Basic EPS [+]	($11.22)	($16.50)	($0.57)	($0.28)	($0.70)
Growth	-32.0%	2799.4%	100.3%	-59.6%
Diluted EPS [+]	($11.22)	($16.50)	($0.57)	($0.28)	($0.70)
Growth	-32.0%	2799.4%	100.3%	-59.6%

Shares outstanding (basic) [+]	1.4	0.9	16.6	13.6	10.5
Growth	55.0%	-94.7%	21.8%	29.8%
Shares outstanding (diluted) [+]	1.4	0.9	16.6	13.6	10.5
Growth	55.0%	-94.7%	21.8%	29.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.